This week, we chat with Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, about tumour acidity, and Gene Mack, president and CEO of Gain Therapeutics, about developing allosteric therapies, including taking Parkinson’s disease treatments beyond addressing symptoms.
Times:
03:03 Gain Therapeutics
25:48 Dyve Biosciences
Gain Therapeutics
Gain Therapeutics is developing next-generation allosteric therapies. Its lead drug candidate, rexaceract is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a phase 1b clinical trial.
Rexaceract has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Also, it has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumours.
Its approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its Magellan platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Dyve Biosciences
Ryan Beal, a cancer survivor and founder and CEO of Dyve Biosciences, invented a first-of-its-kind therapy that delivers sodium bicarbonate through the skin to target tumour acidity throughout the body. The therapy is designed to address a key limitation of earlier efforts, which relied on delivering large amounts of buffering agents orally.
In preclinical research with Moffitt Cancer Center, DYV800 made tumours substantially less acidic, restored T-cell activity, slowed tumour growth and improved survival. The findings were recently published in Frontiers in Immunology, and the next step is bringing the therapy to patients.
To get in touch with guest suggestions, or to sponsor or advertise on the podcast, please email jim@deeptechdigest.com
